3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 87 points (0.5%) at 16,266 as of Friday, Dec. 20, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,274 issues advancing vs. 691 declining with 120 unchanged.

The Drugs industry currently sits up 1.4% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 4.7%, Regeneron Pharmaceuticals ( REGN), up 0.9%, Celgene Corporation ( CELG), up 1.6%, Amgen ( AMGN), up 1.2% and Biogen Idec ( BIIB), up 0.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.17 (-0.3%) to $58.73 on heavy volume. Thus far, 2.7 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $58.70-$59.20 after having opened the day at $59.10 as compared to the previous trading day's close of $58.90.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $73.7 billion and is part of the health care sector. The company has a P/E ratio of 11.8, below the S&P 500 P/E ratio of 17.7. Shares are up 24.6% year to date as of the close of trading on Thursday. Currently there are no analysts that rate AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.53 (-1.2%) to $129.22 on heavy volume. Thus far, 863,812 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $128.52-$131.68 after having opened the day at $131.48 as compared to the previous trading day's close of $130.75.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $25.2 billion and is part of the health care sector. The company has a P/E ratio of 72.7, above the S&P 500 P/E ratio of 17.7. Shares are up 37.2% year to date as of the close of trading on Thursday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Actavis ( ACT) is down $1.83 (-1.1%) to $163.46 on light volume. Thus far, 534,293 shares of Actavis exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $162.35-$165.59 after having opened the day at $165.40 as compared to the previous trading day's close of $165.29.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $28.7 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers